Photodynamic Therapy With Methyl Aminolevulinate for Prevention of New Skin Lesions in Transplant Recipients: A Randomized Study

Wennberg, Ann‐Marie; Stenquist, Bo; Stockfleth, Eggert; Keohane, S.G.; Lear, John T.; Jemec, Gregor B. E.; Mørk, Cato; Christensen, Eidi; Kapp, Alexander; Sølvsten, Henrik; Talme, Toomas; Berne, Berit; Forschner, T.

doi:10.1097/tp.0b013e318180731e

Cited by 98 publications

(77 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BCC is the commonest skin cancer and superficial lesions are often low risk but multiple. PDT is an effective treatment modality for large, multiple, superficial, low risk tumours, field carcinogenesis or dysplasia, as well as in cases when repeated treatments are needed 3 such as immunosuppressed patients, including organ transplant recipients 5 . AK and sBCC respond better to PDT than nodular BCC, arguably due to the fact that the prodrug used is taken up and metabolised more efficiently in the superficial layers of skin than in deeper layers 6 .…”

Section: Introductionmentioning

confidence: 99%

Development of a handheld fluorescence imaging device to investigate the characteristics of protoporphyrin IX fluorescence in healthy and diseased skin

Kulyk

Ibbotson

Moseley

et al. 2015

Photodiagnosis and Photodynamic Therapy

View full text Add to dashboard Cite

3 HighlightsWe developed a handheld device and a time course method for fluorescence imagingThe device can be used to study PpIX formation in healthy and diseased skin PpIX fluorescence grows throughout the 3 hours prior to treatmentThe fluorescence intensity varies between diagnoses and individuals The fluorescence depends on the body site, possibly due to differences in temperature 4 Abstract Background

show abstract

Section: Introductionmentioning

confidence: 99%

Development of a handheld fluorescence imaging device to investigate the characteristics of protoporphyrin IX fluorescence in healthy and diseased skin

Kulyk

Ibbotson

Moseley

et al. 2015

Photodiagnosis and Photodynamic Therapy

View full text Add to dashboard Cite

show abstract

“…102,103 In addition, over the course of 1 year, a single session of MAL-PDT significantly delayed the appearance of new lesions relative to placebo treatment. 104 Over the longer term (≥2 years), MAL-PDT did not appear to reduce the incidence of AKs 105 or SCCs. 106 However, this discrepancy, relative to longer-term outcomes with ALA-PDT, 101 may be explained in part by less frequent follow-up sessions in the MAL-PDT studies.…”

Section: Aks In Organ Transplant Recipientsmentioning

confidence: 99%

Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses

et al. 2015

View full text Add to dashboard Cite

Background Actinic keratosis (AK) and cheilitis (AC) are lesions that develop on photodamaged skin and may progress to form invasive squamous cell carcinomas (SCCs). Objective To provide guidance to Canadian health care practitioners regarding management of AKs and ACs. Methods Literature searches and development of graded recommendations were carried out as discussed in the accompanying introduction (chapter 1 of the NMSC guidelines). Results Treatment of AKs allows for secondary prevention of skin cancer in sun-damaged skin. Because it is impossible to predict whether a given AK will regress, persist, or progress, AKs should ideally be treated. This chapter discusses options for the management of AKs and ACs. Conclusions Treatment options include surgical removal, topical treatment, and photodynamic therapy. Combined modalities may be used in case of inadequate response. AKs are particularly common following the longterm immunosuppression in organ transplant patients, who should be monitored frequently to identify emerging lesions that require surgery.

show abstract

“…Treatment with cyclic ALA-PDT at 4-8 week intervals over a 2-year period on 12 organ transplant recipients led to a significant reduction of SCC (98% mean reduction) [107]. Wennberg et al [108] also found that repeat MAL-PDT treatments reduced the occurrence of new AKs in this special population.…”

Section: Squamous Cell Carcinomamentioning

confidence: 88%

Photodynamic Therapy and Skin Cancer

Papakonstantinou¹,

Löhr²,

Raap³

2018

Dermatologic Surgery and Procedures

View full text Add to dashboard Cite

Non-melanoma skin cancer (NMSC) is the most common type of cancer among white skin individuals worldwide with an increasing incidence over the last years. NMSC is mostly treated with surgical or non-invasive methods such as cryotherapy or topical chemotherapeutics. Over the last years, there has been a rapidly growing interest in the use of photodynamic therapy (PDT) which is a well-tolerated, safe and effective alternative treatment option. PDT involves a photosensitizer, a light source and tissue oxygen and is based on a photo-oxidation reaction in the target tissue which results to a selective destruction of the cancer cells. PDT has been approved for treatment of actinic keratosis, Bowen's disease and basal cell carcinoma in Europe. Off-label uses include treatment of invasive squamous cell carcinoma, cutaneous T-cell lymphoma, Kaposi's sarcoma, Paget's disease and prevention of recurrence of squamous cell carcinoma in organ-transplant recipients. Also combination of PDT with other treatment options such as cryotherapy, surgery and topical therapies has been reported with improved efficacy, tolerability and long-term results. Development of novel photosensitizers and light sources together with targeted delivery systems will increase specificity, efficiency and treatment field of PDT in the future. This chapter aims to give the reader an overview of the important applications of PDT, including indications, approved treatments, advantages and disadvantages of this method such as future trends.

show abstract

Photodynamic Therapy With Methyl Aminolevulinate for Prevention of New Skin Lesions in Transplant Recipients: A Randomized Study

Abstract: Our results suggest that repeated field photodynamic therapy using topical MAL may prevent new AK in transplant recipients although further studies are needed.

Cited by 98 publications

References 34 publications

Development of a handheld fluorescence imaging device to investigate the characteristics of protoporphyrin IX fluorescence in healthy and diseased skin

Development of a handheld fluorescence imaging device to investigate the characteristics of protoporphyrin IX fluorescence in healthy and diseased skin

Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses

Photodynamic Therapy and Skin Cancer

Contact Info

Product

Resources

About